# Progress Note 06 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Babe Didrikson Zaharias (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML038-SYN-TD
- Date: 1953-08-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rosalind Vasquez-Thornbury, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Preventive Visit
- Services: CPT 99396 (periodic preventive medicine, established patient, age 40 to 64) with CPT 99497 (advance care planning) on the same day

## Chief complaint

Periodic adult preventive visit, on the day of cycle 7 of dostarlimab. **S**

## History of present illness

Ms. Didrikson Zaharias, now 42, comes for her yearly preventive visit on the morning of her seventh dose of dostarlimab. Six weeks ago, at the restaging visit, the tumor had almost gone on MRI and endoscopy, and levothyroxine 75 micrograms was started for immune-related hypothyroidism. She takes it on waking, four hours apart from her iron, and the tiredness and cold hands have gone. Her bowel movements are normal, with no blood, urgency or pain. She is playing 18 holes most days and finished third in a regional event last week. She has had no diarrhea, rash, cough or breathlessness since the cold in June. Her PHQ-9 today is 2. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 42 |
| Active conditions | Mismatch repair-deficient low rectal cancer on dostarlimab with a near-complete response; immune-related hypothyroidism on levothyroxine; iron deficiency anemia, recovering |
| Medicines | Dostarlimab every three weeks; levothyroxine 75 micrograms daily; ferrous sulfate 325 mg on alternate days; levonorgestrel intrauterine device |
| Mood | PHQ-9 2 |

## Health risk assessment

Completed by the patient on a tablet in the waiting room and reviewed with her by Dr. Vasquez-Thornbury. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Very good |
| Psychosocial | Busy with tournaments and the club; worried at times that the cancer will come back; sleeps well |
| Tobacco | Never smoked |
| Alcohol and drugs | A drink once or twice a month; no drugs |
| Physical activity | Golf most days, walking the course; strength work three times a week |
| Nutrition | Has cut red meat to twice a week and eats more vegetables and whole grains |
| Sun exposure | Outdoors most of the day; uses sunscreen inconsistently; wears a visor |
| Sexual and reproductive health | Sex comfortable again since the bleeding stopped; levonorgestrel IUD in place; not planning a pregnancy |
| Safety at home | Feels safe; no one hurts, threatens or controls her; no firearm in the home |
| Road safety | Wears a seat belt; drives long distances between tournaments and stops to rest |
| Activities of daily living | Independent |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, night sweats or weight loss; energy back to normal |
| Eyes | Negative | No vision change; eye examination last year |
| Ears, nose, mouth, and throat | Negative | No mouth sores |
| Cardiovascular | Negative | No chest pain or palpitations |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | Normal bowel movements; no blood, urgency or pain |
| Genitourinary | Negative | Light periods with the IUD; no urinary symptoms |
| Breast | Negative | No lump or nipple discharge |
| Musculoskeletal | Negative | No joint pain or swelling |
| Integumentary | Negative | No rash or itching; no changing moles |
| Neurological | Negative | No headache or numbness |
| Endocrine | Negative | Cold intolerance gone; no thirst |
| Psychiatric | Negative | Mood good; PHQ-9 2; no thoughts of self-harm |

13 systems reviewed. **S**

## Current medications

- Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morning **S**
- Dostarlimab-gxly 50 mg/mL injection, 500 mg intravenously over 30 minutes every 3 weeks, for nine doses (six months) **S**
- Levothyroxine 75 microgram oral tablet, one tablet by mouth each morning on an empty stomach, four hours apart from iron **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/68 mmHg; pulse 62 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 99% on room air; weight 63.6 kg; BMI 22.5 kg/m². All vital signs are synthetic.

TSH: 3.1 mIU/L; Free T4: 1.1 ng/dL; PHQ-9: 2. All results are synthetic.

## Immunizations given today

- Hepatitis B vaccine (adjuvanted, two-dose series), dose 1 **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Fit and well; weight 63.6 kg, BMI 22.5; blood pressure 112/68 |
| Head, eyes, ears, nose, and throat | Normal |
| Neck | Thyroid not enlarged or tender; no lymph nodes |
| Breasts | Examined with her agreement and a chaperone: no mass, skin change or nipple discharge; no axillary nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft, non-tender; no liver enlargement or mass |
| Skin | Sun-damaged skin on the forearms, face and neck; several solar lentigines; no lesion suspicious for melanoma or other skin cancer |
| Musculoskeletal | Full range of movement of the spine, shoulders and hips |
| Psychiatric | Cheerful, quick and engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated for a woman of 42 on immunotherapy for rectal cancer. Breast screening is due under the current recommendation to screen every two years from 40; a mammogram was ordered. Cervical screening is up to date. Hepatitis B surface antibody was negative before treatment, so the two-dose adjuvanted hepatitis B vaccine was started today; inactivated vaccines are safe on PD-1 blockade. Influenza and COVID-19 vaccines are due when this season's vaccines arrive. Sun protection was discussed in detail because she is outdoors all day. **S**
   - Hepatitis B vaccine dose 1 today; dose 2 at cycle 9.
   - Screening mammogram ordered.
   - Influenza and COVID-19 vaccines in the autumn.
   - Broad-spectrum sunscreen of SPF 30 or more, reapplied every two hours on the course, with a wide-brimmed hat and sun sleeves.
   - Next preventive visit in one year.
2. **Immune-related hypothyroidism on levothyroxine** (E03.2). TSH 3.1 mIU/L and free T4 1.1 ng/dL six weeks after starting levothyroxine 75 micrograms: replaced, and symptoms gone. **S**
   - Continue levothyroxine 75 micrograms on waking, four hours from iron.
   - TSH and free T4 every six weeks while on dostarlimab.
3. **Mismatch repair-deficient low rectal cancer on dostarlimab** (C20). Near-complete response at three months; cycle 7 today. **S**
   - Cycles 8 and 9 as booked; final restaging after cycle 9.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 112/68 mmHg |
| Depression screening | Completed today | PHQ-9 score 2; item 9 scored 0 |
| Unhealthy alcohol use screening | Completed today | One or two drinks a month |
| Tobacco use | Completed today | Never smoked |
| Intimate partner violence screening | Completed today | Negative; she feels safe |
| Breast cancer screening | Ordered | Mammogram every two years from 40; first screening mammogram ordered |
| Cervical cancer screening | Up to date | HPV and cytology co-test two years ago, normal; next in three years |
| Colorectal cancer screening | Not indicated | Screening does not apply: she is under cancer surveillance with MRI, endoscopy and colonoscopy |
| HIV, hepatitis B and hepatitis C screening | Up to date | All negative before treatment; hepatitis B surface antibody negative |
| Prediabetes and diabetes screening | Not indicated | BMI 22.5 with no other risk factor; fasting glucose normal before each cycle |
| Lipid screening | Up to date | Lipid panel three years ago normal |
| Skin cancer prevention counseling | Completed today | Sun protection for an outdoor athlete; skin examined, no suspicious lesion |
| Hepatitis B vaccine | Completed today | Dose 1 of the two-dose adjuvanted series; dose 2 in one month or later |
| Influenza vaccine | Due | When this season's vaccine is available |
| COVID-19 vaccine | Due | This season's vaccine in the autumn |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap five years ago |
| Recombinant zoster vaccine | Not indicated | Recommended from 50, or from 19 for immunosuppression; PD-1 blockade alone is not immunosuppressive treatment |
| Contraception counseling | Completed today | Levonorgestrel IUD continued during treatment and for at least four months after the last dose |
| Dental and vision examination | Due | Dental cleaning due; eye examination next year |

## Advance care planning

Voluntary advance care planning discussion of about 20 minutes, with her consent. She named a health care agent, recorded in the confidential part of the chart and not named here, and completed a health care proxy form. She said that she wants every treatment with a real chance of controlling the cancer, including surgery and a colostomy if the tumor ever regrows, and wants to be told the facts at once and in plain words. If she were ever too ill to decide and unlikely to recover, she would want care aimed at comfort, with her pain fully treated. To be revisited at each change in her health and at least yearly. **S**

## Guideline basis

- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Breast Cancer: Screening (2024), U.S. Preventive Services Task Force
- Cervical Cancer: Screening (2018), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention

## Follow-up

- Cycle 7 today; cycles 8 and 9 as booked; hepatitis B dose 2 at cycle 9; mammogram; final restaging after cycle 9. Next preventive visit in one year. **S**
- Next scheduled visit 1953-10-05: after nine doses: final restaging, clinical complete response, and the watch-and-wait surveillance plan. **S**
